Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
Dose/route boundary: two 2.5 mg Androderm systems were applied nightly in a randomized hypogonadism trial, delivering 5 mg/day within the card’s 4-8 mg/day range.
Sixty-six adult hypogonadal men (22-65 years of age) were withdrawn from prior i.m. treatment for 4-6 weeks and then randomly assigned to treatment with TTD (two 2.5-mg systems applied nightly) or i.m. (200 mg injected every 2 weeks); there were 33 patients per group.
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. The Journal of clinical endocrinology and metabolism · 1999 · PMID 10522982
Evidence scope. Human, hypogonadal men (n=33 TTD arm), transdermal Androderm system, 24-week RCT.
Primary safety: transient patch-site irritation occurred in 60% and caused 9% to discontinue treatment.
Transient skin irritation from the patches was reported by 60% of the TTD patients, but caused only three patients (9%) to discontinue treatment. i.m. treatment produced local reactions in 33% of patients and was associated with significantly more abnormal hematocrit elevations (43.8% of patients) compared with TTD treatment (15.4% of patients).
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. The Journal of clinical endocrinology and metabolism · 1999 · PMID 10522982
Evidence scope. Human, hypogonadal men, transdermal Androderm, 24-week RCT; local/mild AE incidence only.
Dose/frequency confirmation: nightly 24-hour Androderm at 5 mg/day produced physiologic replacement in adult hypogonadal men.
For the treatment of adult hypogonadal men, the nightly 24 h application of the Androderm testosterone transdermal system (5 mg per day) achieves this goal - as demonstrated in a series of clinical pharmacokinetic studies.
New clinical applications of transdermal testosterone delivery in men and women. Journal of controlled release : official journal of the Controlled Release Society · 2000 · PMID 10699290
Evidence scope. Human, adult hypogonadal men; review/secondary-source synthesis, not new primary data.
Mechanism/route: controlled transdermal testosterone delivery avoids hepatic first pass and reproduces diurnal testosterone rhythm without injection peaks and troughs.
Transdermal administration delivers testosterone at a controlled rate into the systemic circulation, avoiding hepatic first pass and reproducing the diurnal rhythm of testosterone secretion and without the peak and trough levels observed with the use of the traditional long-acting testosterone injections.
Transdermal testosterone delivery: testosterone patch and gel. World journal of urology · 2003 · PMID 14551721
Evidence scope. General transdermal-route pharmacology review (patch + gel); mechanism is route-level, not Androderm-brand-specific data.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Exact current product dose: one 4 mg/day patch at bedtime. The checked abstracts used the older 2.5 mg systems totaling 5 mg/day; they support the displayed 4-8 mg range and nightly route, but not the exact modern 4 mg patch.